Argitalpenak (35) María Gabriela Rodríguez Macías argitalpenak

2024

  1. Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA Registry

    Cancer

2023

  1. Clinical outcomes after CPX-351 in patients with high-risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry

    Cancer Medicine, Vol. 12, Núm. 14, pp. 14892-14901

  2. Frequent Emergence of Resistance Mutations Following Complex Intra-Host Genomic Dynamics in SARS-CoV-2 Patients Receiving Sotrovimab

    Antimicrobial agents and chemotherapy, Vol. 67, Núm. 7, pp. e0026623

  3. Novel Candidate loci and Pathogenic Germline Variants Involved in Familial Hematological Malignancies Revealed by Whole-Exome Sequencing

    Cancers, Vol. 15, Núm. 3

  4. Role of Intracellular Drug Disposition in the Response of Acute Myeloid Leukemia to Cytarabine and Idarubicin Induction Chemotherapy

    Cancers, Vol. 15, Núm. 12

2022

  1. Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry

    Cancers, Vol. 14, Núm. 9

  2. Implementation of a hospital-at-home (HAH) unit for hematological patients during the COVID-19 pandemic: safety and feasibility

    International Journal of Hematology, Vol. 115, Núm. 1, pp. 61-68

  3. Practical tips for managing FLT3 mutated acute myeloid leukemia with midostaurin

    Expert Review of Hematology, Vol. 15, Núm. 3, pp. 203-214

2021

  1. Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group

    Leukemia and Lymphoma, Vol. 62, Núm. 12, pp. 2928-2938

  2. Clinical utility of targeted next-generation sequencing for the diagnosis of myeloid neoplasms with germline predisposition

    Molecular Oncology, Vol. 15, Núm. 9, pp. 2273-2284

  3. Evolving treatment patterns and outcomes in older patients (≥60 years) with AML: changing everything to change nothing?

    Leukemia, Vol. 35, Núm. 6, pp. 1571-1585

  4. Genetic biomarkers identify a subgroup of high-risk patients within low-risk NPM1-mutated acute myeloid leukemia

    Leukemia and Lymphoma, Vol. 62, Núm. 5, pp. 1178-1186

  5. Next generation cytogenetics in myeloid hematological neoplasms: Detection of cnvs and translocations

    Cancers, Vol. 13, Núm. 12

2020

  1. A retrospective cohort of invasive fusariosis in the era of antimould prophylaxis

    Medical Mycology, Vol. 58, Núm. 3, pp. 300-309

  2. COVID-19 coagulopathy: An in-depth analysis of the coagulation system

    European Journal of Haematology, Vol. 105, Núm. 6, pp. 741-750

  3. Exome sequencing reveals heterogeneous clonal dynamics in donor cell myeloid neoplasms after stem cell transplantation

    Haematologica

  4. Plzf-rarα, npm1-rarα, and other acute promyelocytic leukemia variants: The pethema registry experience and systematic literature review

    Cancers, Vol. 12, Núm. 5

  5. Practical Considerations for Treatment of Relapsed/Refractory FLT3-ITD Acute Myeloid Leukaemia with Quizartinib: Illustrative Case Reports

    Clinical Drug Investigation, Vol. 40, Núm. 3, pp. 227-235

2019

  1. A case-control study of real-life experience with ceftolozane-tazobactam in patients with hematologic malignancy and pseudomonas aeruginosa infection

    Antimicrobial Agents and Chemotherapy, Vol. 63, Núm. 2

  2. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis

    The Lancet Infectious Diseases, Vol. 19, Núm. 9, pp. 988-1000